

Table of contents

| | |
|---|------------|
| Abstract | I |
| Kurzzusammenfassung/ Abstract in German | III |
| 1. Introduction | 1 |
| 1.1 Cannabis: The Dualism of Illicit Drug and Remedy | 1 |
| 1.2 Chemical Aspects and Terminology..... | 2 |
| 1.2.1 THC Synthesis..... | 4 |
| 1.3 Principles of Cannabinoid Pharmacology | 6 |
| 1.3.1 The Endocannabinoid System..... | 9 |
| 1.3.2 Medical Applications | 10 |
| 1.4 Cannabinoid Analogs based on the Coumarin Motif | 11 |
| 1.4.1 Coumarin Synthesis..... | 12 |
| 1.5 Drug Development | 13 |
| 1.6 Drug Delivery and Controlled Release Systems | 15 |
| 1.6.1 Temporal Control of Drug Levels..... | 15 |
| 1.6.2 Distributional Control of Drug Levels | 17 |
| 1.6.3 Micro and Nanoparticulate Carrier Systems | 18 |
| 2. Aim of the Project | 21 |
| 3. Results and Discussion | 23 |
| 3.1 Work on the THC-Framework | 23 |
| 3.1.1 Retrosynthetic Aspects..... | 23 |
| 3.1.2 Synthetic Work on the THC Framework | 26 |
| 3.2 Synthetic Cannabinoid Analogs based on the Coumarin Motif | 35 |
| 3.2.1 Synthesis of Salicylic Aldehydes | 36 |
| 3.2.2 3-Benzylcoumarins..... | 43 |
| 3.2.3 3-Pyridylmethylcoumarins | 47 |

| | | |
|--------------|---|------------|
| 3.2.4 | 3-Alkylcoumarins..... | 50 |
| 3.2.5 | 3-Arylcoumarins..... | 53 |
| 3.2.6 | 3-Styrylcoumarins | 59 |
| 3.2.7 | 2,2-Dimethyl-2 <i>H</i> -chromenes..... | 61 |
| 3.3 | Controlled Release Systems for Cannabinoids..... | 64 |
| 3.3.1 | Solubility and Quantification of the Coumarins | 66 |
| 3.3.2 | Microparticle Formulation Screening | 68 |
| 3.3.3 | Encapsulation of coumarins | 77 |
| 3.3.4 | Release experiments..... | 86 |
| 4. | Conclusion and Outlook..... | 93 |
| 4.1 | Work on the THC-Framework | 93 |
| 4.2 | Cannabinoid Analogs | 94 |
| 4.3 | Controlled Release systems for Cannabinoids | 98 |
| 5. | Experimental Part..... | 101 |
| 5.1 | Miscellaneous | 101 |
| 5.1.1 | Analytics and Equipment | 101 |
| 5.1.2 | Preparative work..... | 104 |
| 5.2 | Synthesis and Characterization..... | 105 |
| 5.2.1 | General Procedures | 105 |
| 5.2.2 | Synthesis and Characterization THC Framework (Chapter 3.1)..... | 108 |
| 5.2.3 | Synthesis and Characterization Salicylic Aldehydes (Chapter 3.2.1)..... | 119 |
| 5.2.4 | Synthesis and Characterization 3-Benzylcoumarins (Chapter 3.2.2)..... | 140 |
| 5.2.5 | Synthesis and Characterization 3-Pyridylmethylcoumarins (Chapter 3.2.3) ... | 158 |
| 5.2.6 | Synthesis and Characterization 3-Alkylcoumarins (Chapter 3.2.4)..... | 176 |
| 5.2.7 | Synthesis and Characterization 3-Arylcoumarins (Chapter 0)..... | 232 |
| 5.2.8 | Synthesis and Characterization 3-Styrylcoumarins (Chapter 3.2.6) | 255 |
| 5.2.9 | Synthesis and Characterization 2,2-Dimethyl-2 <i>H</i> -chromenes (Chapter 3.2.7) | 256 |

| | | |
|-----------|--|------------|
| 5.3 | Materials and Methods Controlled Release Systems (Chapter 3.3) | 260 |
| 5.3.1 | Additional data Chapter 3.3 | 264 |
| 5.4 | Crystallographic Data | 266 |
| 6. | List of Abbreviations | 274 |
| 7. | Literature..... | 282 |
| 8. | Appendix..... | 296 |
| 8.1 | Curriculum Vitae | 296 |
| 8.2 | Publications and Conference Contributions | 300 |
| 8.3 | Acknowledgements | 302 |